February 10-11, 2014 The Waldorf Astoria New York Now in its sixteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies, with a special focus on select established private companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

Reasons Top 10 to attend 1 35% of the biotechs who filed an IPO in 2013 will be presenting at this year’s BIO CEO & Investor Conference. 2 Hear the Washington perspective on the Affordable Care Act and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables.

5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2014. 6 Gain access to BIO’s 1x1 Partnering SystemTM for scouting potential investments and deal partners, optimizing your time at the event. 7 Hear presentations from more than 150 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences.

8 Get the pulse of the current and proposed investment trends in biotechnology. 9 Network with peers, investors, and potential partners attending the conference and our exclusive receptions.

-2- Who Should Attend?

Audience Profile

Conference Size 1,400 One-on-One PartneringTM Meetings 1,350+ Investors Attending 700 Company Presentations 150 Market Cap

>$1B+: 9%

500M-1B companies <50M 8% 300+ 24% Nearly 700 investors 250-500M 16%

50-100M 20% 100-250M 23%

Rare/Genetic Therapeutic Focus Diseases: 2% Gastrointestinal Ophthalmology Disorders: 2% 2% Vaccines: 2% Diagnostics: 2%

Renal: 3% 3D Metabolic: 4% Oncology 130/160/20/35 Cardiovascular 29% 4% Infectious Over 1,400 attendees Diseases: 6% CNS from 20 different countries 13% Cell Therapy/ Other Regenerative 10% Over 35% of attendees Medicine: 6% are executives Autoimmune/ : 6% Platform/ Discovery: 9%

-3-

3D 130/160/20/35 Fireside Chats

Fireside Chats feature candid discussions between biopharma executives, Wall Street analysts, and other high-level industry experts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2014.

Leonard Bell, M.D. CEO,

Belén Garijo, M.D. President & CEO Merck Serono

Richard F. Pops Chairman & CEO plc

David E.I. Pyott Chairman of the Board & CEO

Christopher A. Viehbacher CEO, Sanofi Chairman, Genzyme

-4- Plenary Sessions

Opening Remarks • James C. Greenwood, President & CEO, Biotechnology Industry Organization

Opening Plenary: A Room with a (Buy-Side) View: The Year Ahead Monday, February 10th, 12:00pm – 12:55pm Join us for a scenic view of 2014 with portfolio managers and senior buy-side analysts. This lively panel discussion will be primed with the results of this year’s Investor Perception Study, conducted by BIO’s Industry Analysis Team and International Strategy & Investment (ISI). Panelists will field a range of questions on the peaks and valleys of the 2014 landscape, from valuations and volatility to challenges and opportunities facing institutional investors today. Moderator: • Mark Schoenebaum, MD, Senior Managing Director, ISI Group Panelists: • Andrew Acker, CFA, Portfolio Manager, Janus Global Life Sciences • Oleg Nodelman, Founder & Managing Director, EcoR1 Capital • William S. Slattery, Partner, Deerfield Management Company

Closing Plenary: Fundraising in the New Capital Market Environment Tuesday, February 11th, 4:00pm – 4:55pm 2013 was clearly the year of the IPO. As a result, a dynamic fundraising environment emerged last year. Many biotechs took full advantage of this market to raise capital - through follow-ons and PIPEs after their initial debut. What’s next? What challenges will await these newly public companies in 2014, or those private biotechs waiting in the wings? Hear industry experts discuss why the markets are doing well and what effect it has had on the entire biotech ecosystem. What’s their advice on how can we keep the momentum, and what do biotech CEOs need to look out for in 2014? Moderator: • Jonathan L. Kravetz, Chair of the Securities Practice Group, Mintz Levin Panelists: • John Chambers, Managing Director, Head of Healthcare Investment Banking, ROTH Capital Partners • David-Alexandre Gros, MD, Executive Vice President, Chief Strategy Officer, Sanofi

Speakers added daily. -5- Therapeutic Workshops

Delivering the [RNAi] Goods Monday, February 10th, 10:30am - 11:25am Investing in the RNA space? What delivery technology will win the race to turn these novel molecules into ap- proved therapies? Is there a “winner take all” in this space or does each type of nucleic acid technology require a unique platform for delivery? This panel will discuss ongoing innovation in the nanoparticle, liposomal, nucleic acid, and conjugate-based approaches to delivering one of the most promising modalities in biotech. Panelists: • Douglas Fambrough, PhD, CEO, Dicerna Pharmaceuticals • Bruce Given, MD, Chief Operating Officer, Arrowhead Research Corporation • John Maraganore, PhD, Chief Executive Officer, • Kleanthis G. Xanthopoulos, PhD, President & CEO, Regulus Therapeutics Balancing the Risk-Reward in Rare Disease Drug Development Monday, February 10th, 2:00pm – 2:55pm There were certainly positive developments in the rare diseases space last year – as we saw with the success of recent IPOs and new deals. These possibilities of large returns often outweigh the inherent risk involved, and while the path to approval is not always as straightforward as it seems, success is there to be had. Challenges also exist throughout development however, from validating endpoints and reimbursement costs, to the difficulties of trial recruitment. How do you navigate this dynamic environment? CEOs of companies paving the way will be on-hand to discuss the advantages and challenges involved in bringing rare disease treatments to market, and industry experts will dissect some of the myths that have revolved around the space. Panelists: • Timothy R. Coté, MD, MPH, Principal & CEO, Coté Orphan Consulting • Hans GCP Schikan, PharmD, Chief Executive Officer, Prosensa Keeping an “I” on Oncology: The ASCO Immunotherapy Preview Tuesday, February 11th, 1:30pm – 2:25pm Immuno-oncology has been earning the spotlight over the past year, having been named as Science’s Breakthrough of the Year, and this year’s ASCO will be no exception. Expert panelists will discuss the latest developments in the immuno-oncology space. What will be the talk of ASCO? What does it take to get breakthrough status? Why has this field taken so long to come to fruition? Are immunotherapies the answer to managing cancer over a lifetime? Panelists: • Annalisa Jenkins, MBBS, MRCP, Executive VP & Head of Global Research and Development, Merck KGaA • Michael G. King, Jr., Senior Analyst, Biotechnology, JMP Securities • Anthony S. Marucci, Founder, President, CEO & Director, Celldex Therapeutics • Jon Wigginton, MD, Senior Vice President, Clinical Research, MacroGenics

-6- Business Roundtables

Solution Development: Aiming the Whole Pipeline at a Single Goal Monday, February 10th, 9:00am - 9:55am One model for maximizing biotech value creation is ‘Solution Development’, which calls for a company to develop multiple agents for a single overarching indication, either to identify the best one of many or to develop combinations. The panel will contrast this Solution Development model against the traditional model of developing a single drug for a single indication or multiple drugs but for disparate indications. How will using a Solution Development model impact clinical/regulatory strategy, competitive positioning, financing strategy, and M&A game theory? Moderator: • Peter Kolchinsky, PhD, Managing Director, RA Capital Management, LLC Panelists: • Christopher Anzalone, PhD, President & CEO, Arrowhead Research Corporation • Stanley C. Erck, President & CEO, Novavax • Milind S. Deshpande, PhD, President & CEO, Achillion Pharmaceuticals • Kurt Graves, Chairman, President & CSO, Intarcia Therapeutics The Reimbursement Landscape Under ACA Tuesday, February 11th, 12:00pm – 12:55pm The Affordable Care Act brings a great promise to the biotech industry and our nation as a whole. Now, a couple months in, what do we know? What pressure will ACA put on the forces that impact product reimbursement, and how will those forces respond? What can the biomedical ecosystem do to protect the industry’s pipelines? How did – and have - companies prepared? Come hear a discussion among industry representatives on this new environment under ACA, and get their take on where the law will lead one of the most important elements of biotech development. Panelists: • J.D. Kleinke, Healthcare Business Strategist • Laurel Todd, Managing Director, Reimbursement & Health Policy, BIO Let’s Make a Deal – Strategic Licensing and M&A Trends Tuesday, February 11th, 9:00am - 9:55am This panel will evaluate licensing and M&A trends of recent deals as the parties involved aim to get the biggest bang for their buck. Why have these trends developed and what is in store for the future? What do small company executives and investors think about recent valuations, CVRs, and the timing of deals with respect to stage of development? Hear industry experts speak on the differing licensing challenges and solutions facing both large and small companies. Moderator: • Effie Toshav, Partner, Fenwick & West LLP Panelists: • Michael Diem, Global Vice President & Head of Corporate Strategy, AstraZeneca

Speakers added daily. -7- Agenda*

Duke of 1x1 Monday, Conrad Windsor Park South Basildon East Foyer Jade/Astor Timeslots February 10, 2014 4th Floor 3rd Floor 8th Floor 7:00 – 7:55am Networking Breakfast (Grand Ballroom) 1x1 (1 & 2) 8:00 – 8:45am Fireside Chat with Richard F. Pops, Chairman & CEO, Alkermes plc (Astor)

Galena Celator Affimed Intrexon Auxilium Business 9:00 – 9:25am Pharmaceuticals Roundtable: 1x1 (3) Biopharma Pharmaceuticals Kids V Cancer (PAG) Corporation Solution Development: Covagen Aiming the NovaBay 9:30 – 9:55am Agenus Relypsa Prosensa Whole Pipeline at 1x1 (4) Pharmaceuticals a Single Goal (Jade)

Synthetic Sutro Biopharma Regado ZIOPHARM 1x1 (5) 10:00 – 10:25am CytoDyn Biologics Biosciences Oncology Mirna Therapeutics

Mast Cerecor OncoMed Lexicon 10:30 – 10:55am Prima BioMed 1x1 (6) Therapeutics KemPharm Pharmaceuticals Pharmaceuticals Therapeutic Workshop: Delivering the Epilepsy Foundation (RNAi) Goods Innovus Cyclacel (PAG) Onconova Synergy (Jade) 1x1 (7) 11:00 – 11:25am Pharmaceuticals Pharmaceuticals Therapeutics Pharmaceuticals ALS TDI (PAG) Opexa Immune Pharmaceutical Northwest 1x1 (8) 11:30 – 11:55am Therapeutics Pharmaceuticals Biotherapeutics Karo Bio AB KineMed 12:00 – 12:55pm Opening Plenary Session: A Room with a (Buy-Side) View: The Year Ahead (Astor) – Box Lunch

Melanoma Research Alliance (PAG) Anavex Life Conatus 1x1 (11) 1:00 – 1:25pm Sciences Corp. NeoStem Pharmaceuticals Mesoblast Immune Design

Probiodrug AG ImmunoCellular Navidea 1:30 – 1:55pm GenSpera Resverlogix 1x1 (12) Nuron Biotech Therapeutics

Newron Anthera Five Prime Rigel Therapeutic 2:00 – 2:25pm Pharmaceuticals DARA BioSciences Workshop: 1x1 (13) S.p.A. Pharmaceuticals Therapeutics Pharmaceuticals Balancing the Risk-Reward in Rare Disease CytRx Rexahn StemCells BioLineRx Stallergenes Drug 1x1 (14) 2:30 – 2:55pm Corporation Pharmaceuticals Development (Jade) Progenics 3:00 – 3:25pm Soligenix TG Therapeutics Stem Cell Therapeutics Biotie Therapies Pharmaceuticals 1x1 (15) Amarantus Immunovaccine Repros Fireside Chat: 1x1 (16) 3:30 – 3:55pm GTx BioScience Alcobra Therapeutics Christopher A. Viehbacher Celsus Galectin Tonix Keryx CEO, Sanofi OncoSec Medical 1x1 (17) 4:00 – 4:25pm Therapeutics Therapeutics Pharmaceuticals Biopharmaceuticals (Astor)

La Jolla Sorrento Bavarian Nordic 4:30 – 4:55pm Pharmaceutical Intra-Cellular Therapies Chimerix 1x1 (18) Company Therapeutics A/S 5:00 – 6:30pm BIO CEO Reception (Empire Room)

Speakers added daily. -8- Duke of 1x1 Tuesday, Conrad Windsor Park South Basildon East Foyer Jade/Astor Timeslots February 11, 2014 4th Floor 3rd Floor 8th Floor 7:00 – 7:55am Networking Breakfast (Grand Ballroom) 8:00 – 8:45am Fireside Chat with David E.I. Pyott, CEO and Chairman of the Board, Allergan (Astor) 1x1 (20/21) Opsona Therapeutics 8:30 – 8:55am Tekmira Trovagene Ophthotech Exelixis 1x1 (22) Pharmaceuticals Nora Therapeutics

Benitec Argos Therapeutics Ohr AcelRx Business 9:00 – 9:25am Retrophin Pharmaceuticals Roundtable: 1x1 (23) Biopharma Polynoma Pharmaceutical Let’s Make a Deal – Strategic Aduro BioTech Apricus Columbia Arena Licensing and 9:30 – 9:55am pSiVida Pharmaceuticals M&A Trends 1x1 (24) Biosciences Laboratories Kadmon Corporation (Jade) SciClone 10:00 – 10:25am Cytokinetics SYGNIS AG 1x1 (25) TxCell SA Pharmaceuticals

Novelos Aradigm CymaBay Therapeutics Inovio 10:30 – 10:55am OvaScience 1x1 (26) Therapeutics Corporation MaxCyte Pharmaceuticals

Trevena

ProMetic Life 11:00 – 11:25am TiGenix N.V. OXiGENE Heat Biologics Fireside Chat: 1x1 (27) Sciences Leonard Bell, Immunocore MD, CEO, Alexion (Astor)

RXi Cleveland Pieris AG Stemline Regulus 11:30 – 11:55am 1x1 (28) Pharmaceuticals BioLabs XDx Therapeutics Therapeutics Fireside Chat: 12:00 – 12:55pm Business Development: Belén Garijo, MD, President and CEO, 1x1 (29) (Box Lunch) The Reimbursement Landscape Under ACA (Jade) Merck Serono (Astor)

Catalyst ReNeuron BIND 1:00 – 1:25pm Pharmaceutical Codexis Cempra 1x1 (30) Partners Group plc Therapeutics Therapeutic SIGA Advanced Cell KaloBios Alnylam 1x1 (31) 1:30 – 1:55pm Technologies Technology MetaStat Pharmaceuticals Pharmaceuticals Workshop: Keeping an “I” on Oncology: Swedish The ASCO 2:00 – 2:25pm GENFIT Athersys Ignyta Horizon Pharma Orphan Immunotherapy 1x1 (32) Biovitrum AB Preview (Jade)

Idera Orexigen 1x1 (33) 2:30 – 2:55pm AntriaBio Targacept Selvita S.A. Pharmaceuticals Therapeutics

Tetraphase 1x1 (34) 3:00 – 3:25pm DiaMedica Neuralstem CEL-SCI Corporation Pharmaceuticals Verastem

Transition PDL 1x1 (35) 3:30 – 3:55pm Biodel Therapeutics Advaxis Epizyme BioPharma 4:00 – 4:55pm Closing Plenary: Fundraising in the New Capital Market Environment (Astor) 5:00 – 6:00pm Closing Happy Hour (Silver Corridor)

Blue: Private Company • PAG: Patient Advocacy Group * As of 1/15. Program schedule subject to change. Please go to www.bio.org/bioceo or visit us onsite for updates.

-9- Presenting Companies Sold Out!

The 2014 BIO CEO & Investor Conference will better accommodate the growing diversity of investors and companies. While the majority of presenting companies at this event are publicly traded, with about half trading with market capitalizations above $100M, this meeting with once again feature a unique track of 30 high-caliber and established private company presentations. Presenting Companies* PUBLIC COMPANIES Epizyme Ophthotech Verastem AcelRx Pharmaceuticals Exelixis Orexigen Therapeutics ZIOPHARM Oncology Five Prime Therapeutics OvaScience Advanced Cell Technology PRIVATE COMPANIES Advaxis Galectin Therapeutics OXiGENE Agenus PDL BioPharma Aduro BioTech Alcobra Pharma GENFIT Prima BioMed Affimed Therapeutics Alexion Pharmaceuticals GenSpera Progenics Pharmaceuticals ALS Therapy Development Institute Alkermes plc Gilead Sciences ProMetic Life Sciences Argos Therapeutics Allergan GTx Prosensa Cerecor Alnylam Pharmaceuticals Heat Biologics pSivida Corp. Covagen Amarantus BioScience Horizon Pharma Regado Biosciences Holdings Idera Pharmaceuticals Regulus Therapeutics CymaBay Therapeutics Anavex Life Sciences Corp. Ignyta Relypsa Epilepsy Foundation Immune Pharmaceuticals ReNeuron Group plc Immune Design Corporation AntriaBio ImmunoCellular Therapeutics Immunocore Apricus Biosciences Immunovaccine Resverlogix Corp. Kadmon Corporation Aradigm Corp. Innovus Pharmaceuticals Retrophin KemPharm Arena Pharmaceuticals Inovio Pharmaceuticals Rexahn Pharmaceuticals Kids v Cancer Athersys Intra-Cellular Therapies Rigel Pharmaceuticals KineMed Auxilium Pharmaceuticals Intrexon Corporation RXi Pharmaceuticals MaxCyte Bavarian Nordic A/S KaloBios Pharmaceuticals Sanofi Melanoma Research Alliance Benitec Biopharma Karo Bio AB SciClone Pharmaceuticals Melinta Therapeutics BIND Therapeutics Keryx Biopharmaceuticals Selvita S.A. Mirna Therapeutics Biodel La Jolla Pharmaceutical SIGA Technologies Nora Therapeutics BioLineRx Company Soligenix Nuron Biotech Biotie Therapies Corp. Sorrento Therapeutics Opsona Therapeutics Catalyst Pharmaceutical Mast Therapeutics Stallergenes Pieris AG Partners Merck Serono Stem Cell Therapeutics Polynoma Celator Pharmaceuticals Mesoblast StemCells Probiodrug CEL-SCI Corporation MetaStat Stemline Therapeutics Proteon Therapeutics Celsus Therapeutics Navidea Biopharmaceuticals Swedish Orphan Biovitrum AB Sutro Biopharma Cempra NeoStem SYGNIS AG Trevena Chimerix Neuralstem Synergy Pharmaceuticals TxCell SA Cleveland BioLabs Newron Pharmaceuticals Synthetic Biologics Ultragenyx Codexis S.p.A. Targacept Columbia Laboratories Northwest Biotherapeutics Tekmira Pharmaceuticals XDx NovaBay Pharmaceuticals Corporation Conatus Pharmaceuticals * As of 01/14/2014 Cyclacel Pharmaceuticals Novelos Therapeutics Tetraphase Pharmaceuticals CytoDyn OHR Pharmaceuticals TG Therapeutics Cytokinetics OncoMed Pharmaceuticals TiGenix N.V. CytRx Corporation Onconova Therapeutics Tonix Pharmaceuticals DARA BioSciences OncoSec Medical Transition Therapeutics DiaMedica Opexa Therapeutics Trovagene

-10- Participating Investors

Participating Investors* China Private Equity Group, Little Gem Life Sciences RTW Investments Crown Point Group Livingston Securities RusBio Ventures Up 60% over Dabar Investment Associates Loeb Partners Samtheo Biopharma Dalek Capital Management Logical Ventures Sands Capital last year! Eachwin Capital LP Loncar Family Serrado Capital Early Harvest Fund Long Wharf Investors, Inc. SimRx Easton Capital LSWorks Sio Capital Management 21st Century Investors EcoR1 Capital Lumira Capital Slater Technology Fund Aceras Biomedical Edgewood Management Magna Group Capital SLC Management Aegis Capital Corp. Edison Investment Research Markston International Small Business Technology Investment Fund Akana Healthcare Capital EGB Advisors, Maxim Group Somerset Capital Group, Ltd. American Capital Emerald Advisers, Inc. Maz Capital Advisors Spencer Edwards Investment Amici Capital Empire Asset Management Medimmune Ventures, Inc. Stanphyl Capital AmTrust Financial Ennovance Capital MedPro Investors Stifel Anson Group Canada F.B.Asset Management Mehta Partners Strategy Signal Arcus Ventures Favus Institutional Merck Research Stuyvesant Capital Arthritis Foundation MFP Investors FireRock Capital Management Ascendant Capital Midfarm Capital First Island Capital Sunrise Equity Partners Aspire Capital Partners Mitsui Global Investment First Manhattan Company Symmetry Capital Athyrium Capital Management Mizuho Securities Five Corners Capital Inc. Symphony Capital Atika Capital Management Morgan Stanley Fountain Healthcare Partners Syzygy Therapeutics Atlantis Investment Mountain Brook Capital GE Capital, Life Science Management LLC TaiAn Technologies Atlas Capital Finance MP Healthcare Venture Technological & Investment ATP Early Harvest Fund Global Corporate Finance Management, Inc. Horizons Auriga Capital Management Global Energy Capital MSF Capital Advisors Tegris Advisors Avior Capital Goldman Sachs MVP Capital Partnera The Channel Group AZCA Venture Partners Greenwich LifeSciences Needham & Company The Issaquena Trust Bank of America Merrill Lynch Griffin Securities NGN Capital The Keiser Foundation Barclays Halcyon Cabot Partner NJ Investment Division Tryphon Bawcap Hercules Technology Growth Nordcon Capital UBS Bayshore Venture Capital Numoda Capital Innovations US Steel Pension Fund BDC Healthcare Fund HI Investors Capital On-Point Capital V2M Capital Bergmor Capital Horizon Technology Finance Oppenheimer & Co. Inc. Valquest Capital Management Bijan Capital Hutchin Hill Capital Opus Point Partners VAO Partmers Bill and Melinda Gates Iliad Ventures Oracle Investment Var2 Pharmaceuticals Foundation IS Ceske Sporitelny Management venBio Biotech Stock Review Jina Ventures Inc. OrbiMed Advisors Venrock BioYields JMP Securities Outer Islands Capital Veziris Ventures Black Diamond Johnston Associates Oxford Finance Visium Bloom Burton & Co. JPMorgan Pacific Rim Ventures Watervein Partners, Inc. BNY Mellon Knoll Capital Management Palkon Capital Management WBB Securities BofAML Korea-Seoul Life Science Pappas Ventures Weiss Multi-Strategy Boodell & Co Fund (KSLSF) Piper Jaffray Advisers Brean Capital Ladenburg Thalmann Poliwogg Wexford Capital LP Burrage Capital Laidlaw & Company Profit Investments Wolf Capital Management Burrill & Company Landmark Angels, Inc. Questrion World Tech Ventures Cantor Fitzgerald LFP Capital QVT Financial Capital Royalty Life Science Ventures Rockefeller & Co. *As of 01/14/2014 Cato BioVentures LifeScience EquityPartners, Rocker Funder Cedarlane Enterprises inc LifeTech Capital ROTH Capital Partners Cedrus Investments Lincoln Park Capital Roy Healthcare Research

-11- One-on-One Meetings

BIO’s One-on-One Partnering™ System is the interactive environment that allows you to increase your productivity, discover new investment and licensing opportunities, and expand your business potential worldwide. Using the system, companies are able to: • Pre-schedule 30-minute private 1x1 meetings • Source potential collaborations and funding opportunities with an international audience • Communicate directly with prospective investors and C-level executives in biotech and pharma • Search company and investor profiles for potential business partnerships

One-on-One Partnering Statistics

1,380 scheduled meetings in 2013 72% growth in scheduled meetings since 2009 1,600

1,380 1,400 1,327 1,210 1,200

1,000 931 801 800

600

Company to Investor s Scheduled Meetin Total 400 91% 200

0 2009 2010 2011 2012 2013 Year

Company to Company Investor to Investor 6% 3%

-12- Sponsors

Supporting Bank Sponsors

BIO Double Helix Sponsors BIO Helix Sponsors

Conference Supporters

Media Sponsors

Local Co-Host

BIO sponsors receive top-notch customer service, prime brand exposure and recognition from the most influential people in biotech. Let us build a sponsorship package that meets your needs. Contact George MacDougall at 202-292-6689 or [email protected] to get started. For more information on BIO sponsorships, please visit www.bio.org/sponsor

-13- Advisory Committee

Tom Brakel, MD Senior Portfolio Manager & Senior Investment Analyst, Federated Kaufmann Funds John Chambers Managing Director & Head of Healthcare Investment Banking, ROTH Capital Partners

Bernard Davitian Vice President & Managing Director Sanofi-Genzyme BioVentures Michael Hay Vice President, BioMedTracker Product Manager, Sagient Research Systems

Annalisa Jenkins, MBBS, MRCP Executive VP and Head of Global Research and Development, Merck KGaA

Peter Kolchinksky, PhD Managing Partner, RA Capital Management, LLC

Arlene Morris CEO, Syndax Pharmaceuticals

Oleg Nodelman Founder & Managing Director, EcoR1 Capital

David Sable, MD Portfolio Manager, Special Situations Life Sciences Fund

Hans GCP Schikan, PharmD CEO, Prosensa Nathan Tinker, PhD Executive Director New York Biotechnology Association

-14- Reserve your spot today!

3 BIO offers a number of ways for conference attendees to save money on their registration fees.

3 Discounted packages for presenting companies bringing three or more attendees.

3 Special rates for academics and service providers.

Complimentary registration is available to qualified institutional (buy and sell-side), private equity, and venture investors. Go to bio.org/bioceo/register and register now.

REGISTRATION CATEGORIES FEES PRESENTER GROUP PACKAGES* FEES Member $2,095 Public Group Member $6,795 Member Additional $1,595 Public Group Non-Member $9,195 Non-Member $2,795 Private Group Member $5,595 Non-Member Additional $2,795 Private Group Non-Member $7,795 Service Provider Member $4,195 Service Provider Non-Member $5,195 PRESENTATION FEES FEES Academic/Tech Transfer $895 Member Public $2,895 Non-Member Public $3,795 Member Private $1,895 Non-Member Private $2,595

* Includes presentation and registration fees. Hotel Venue The Waldorf Astoria New York 301 Park Avenue Join the conversation: New York, NY 10022 Learn more about Biotechnology at bio.org A limited number of rooms are Engage with the Biotech Community at BIOtech-NOW.org available at the Waldorf Astoria. Please make your reservations Follow us on Twitter @bio1x1 or #BIOCEO14 as soon as possible to secure Become a fan on Facebook (facebook.com/IAmBiotech) your room at the discounted rate.

-15-